PlainPharmaWatch

CMS Open Payments · Program Year 2024

Vaporox, Inc.

Vaporox, Inc. reported $51,752.06 across General Payments, Research, and Ownership to 102 physicians and teaching hospitals across 102 transactions.

See the rankings → How this is sourced
$51.8K Below-median payer
All-tracks total
102 Below-median volume
Transactions
102 Below-median reach
Recipients
−$10.5K
General Payments vs PY2023

Vaporox, Inc. reported $51,752.06 across all CMS Open Payments tracks (General + Research + Ownership) to 102 physicians and teaching hospitals in Program Year 2024 - ranking #1342 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $51,752.06, averaging $507.37 per recipient.

Vaporox, Inc.'s payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

27/100

Total payments

F

10/100

Transaction volume

F

11/100

Physician reach

F

11/100

Payment type diversity

C

77/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer vaporox-inc Vaporox, Inc.

$51.8K · #1342/1,925 · 0.0% industry · PY2024

  • TOT $51.8K
  • RANK #1342
  • SHARE 0.0%
  • TXN 102
  • RCP 102
  • CAT 6
  • GEN $51.8K
  • ΔGEN −$10.5K
  • TOP1 47.1%
  • PY 2024

Volume peers

Nearest volume peer: Merakris Therapeutics, Inc. ($51.8K)

Infinity BiologiX LLC$52.4KMerakris Therapeutics, Inc.$51.8KVaporox, Inc. (this)$51.8KUnited Imaging Healthcare No…$51.7KSteelhead Surgical Inc$51.2K
All-tracks payment totals near Vaporox, Inc. (CMS Open Payments PY2024)

Vaporox, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Vaporox, Inc.'s CMS-reported General Payments decreased by $10.5K (−16.9%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: VAPOROX, INC.PY2023: VAPOROX, INC.PY2024: Vaporox, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$62.3KPY2024$51.8K
PY2023
$62,262.01
PY2024
$51,752.06

What the Data Shows for Vaporox, Inc.

The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Vaporox, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.

The 6-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $42.0K, accounting for 81.2% of this company's General Payments and 19 transactions.

General Payment Breakdown by Type

"Consulting Fee" leads Vaporox, Inc.'s 6-category general-payment breakdown at $42.0K, 81.2% of the reported total.

Vaporox, Inc. reports 6 general-payment categories - the top three are Consulting Fee (81.2%), Food and Beverage (10.8%), and Education (3.9%). The remaining 3 categories make up 4.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Vaporox, Inc. divides its payments

General-payment categories, ordered by reported total

1. Consulting Fee$42.0K2. Food and Beverage$5.6K3. Education$2.0K4. Travel and Lodging$1.5K5. Entertainment$340.006. Compensation for Services…$250.00
Payment Type Amount Transactions
Consulting Fee $42.0K 19
Food and Beverage $5.6K 78
Education $2.0K 1
Travel and Lodging $1.5K 1
Entertainment $340.00 2
Compensation for Services Other Than Consulting $250.00 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $47,063.04 (90.9%) of $51,752.06 in this company's General Payments records across 63 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Vaporox, Inc.

The five named recipients with the highest reported General Payments from this company

Dustin Kruse$24.4KDavid Armstrong$10.0KMichael Duehrssen$7.6KPaul Kesselman$4.4KTraci Kimball$638.30
  1. 1

    Dustin Kruse

    $24,386.82 across 15 reported transactions

  2. 2

    David Armstrong

    $10,000.00 across 1 reported transactions

  3. 3

    Michael Duehrssen

    $7,637.92 across 9 reported transactions

  4. 4

    Paul Kesselman

    $4,400.00 across 3 reported transactions

  5. 5

    Traci Kimball

    $638.30 across 5 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Vaporox, Inc. ranks #1342 of 1,925 by total payments (bottom 30% by spend) but is notably more concentrated than that alone would suggest -- #584 of 1,838 by HHI (top 32% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.

00.30.50.81.12846.22867.32888.52909.72930.8Total payments ($M)Concentration (HHI, 0-10,000)
Vaporox, Inc. (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Vaporox, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Vaporox, Inc..

Medyssey USA, Inc

HHI 2888

NovApproach Spine, LLC

HHI 2890

ImpediMed, Inc.

HHI 2895

Renalytix AI, Inc.

HHI 2909

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Vaporox, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Vaporox, Inc. ranks #1342 of 1,925 by all-tracks total payments, led by "Consulting Fee".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Vaporox, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.